Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Biocryst Pharmaceuticals (BCRX) Short-Term Debt issuances (2019)

Biocryst Pharmaceuticals filings provide 1 years of Short-Term Debt issuances readings, the most recent being $19.5 million for Q1 2019.

On a quarterly basis, Short-Term Debt issuances changed N/A to $19.5 million in Q1 2019 year-over-year; TTM through Dec 2019 was $19.5 million, a N/A change, with the full-year FY2022 number at $73.1 million, changed N/A from a year prior.
Short-Term Debt issuances hit $19.5 million in Q1 2019 for Biocryst Pharmaceuticals.
In the past five years, Short-Term Debt issuances ranged from a high of $19.5 million in Q1 2019 to a low of $19.5 million in Q1 2019.